m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00010)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa-miR-29a-3p
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) [READER]
| In total 2 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | HNRNPA2B1 is a reader of the N(6)-methyladenosine mark in primary-miRNAs and promotes DROSHA processing to precursor-miRNAs. HNRNPA2B1 downregulated hsa-miR-29a-3p, miR-29b-3p, and miR-222 and upregulated miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced breast cancer cellMCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance. | |||
| Target Regulation | Down regulation | |||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
| Responsed Drug | Fulvestrant | Approved | ||
| Pathway Response | TGF-beta signaling pathway | hsa04350 | ||
| Cell Process | Endocrine-resistance | |||
| In-vitro Model | MCF7/LCC9 | Invasive breast carcinoma | Homo sapiens | CVCL_DP52 |
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
| Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | HNRNPA2B1 is a reader of the N(6)-methyladenosine mark in primary-miRNAs and promotes DROSHA processing to precursor-miRNAs. HNRNPA2B1 downregulated hsa-miR-29a-3p, miR-29b-3p, and miR-222 and upregulated miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced breast cancer cellMCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance. | |||
| Target Regulation | Down regulation | |||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
| Responsed Drug | Tamoxifen | Approved | ||
| Pathway Response | TGF-beta signaling pathway | hsa04350 | ||
| Cell Process | Endocrine-resistance | |||
| In-vitro Model | MCF7/LCC9 | Invasive breast carcinoma | Homo sapiens | CVCL_DP52 |
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
Methyltransferase-like 3 (METTL3) [WRITER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
| Response Summary | The knockout of methyltransferase 3 (N6-adenosine-methyltransferase complex catalytic subunit) removed the m6A modification of hsa-miR-29a-3p and reduced miR-29a-3p expression. These findings suggest that miR-29a-3p is a potential target that can be manipulated for ALI/ARDS. | |||
| Target Regulation | Up regulation | |||
| Responsed Disease | Acute respiratory distress syndrome | ICD-11: CB00 | ||
| In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
| In-vivo Model | All the mice were randomly divided into three groups: the normal saline group (NS), the lipopolysaccharide + negative control group (LPS + NC), and the LPS + miR-29a-3p agomir group (LPS + Agomir). | |||
Breast cancer [ICD-11: 2C60]
| In total 2 item(s) under this disease | ||||
| Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | HNRNPA2B1 is a reader of the N(6)-methyladenosine mark in primary-miRNAs and promotes DROSHA processing to precursor-miRNAs. HNRNPA2B1 downregulated hsa-miR-29a-3p, miR-29b-3p, and miR-222 and upregulated miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced breast cancer cellMCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance. | |||
| Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
| Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
| Target Regulation | Down regulation | |||
| Responsed Drug | Fulvestrant | Approved | ||
| Pathway Response | TGF-beta signaling pathway | hsa04350 | ||
| Cell Process | Endocrine-resistance | |||
| In-vitro Model | MCF7/LCC9 | Invasive breast carcinoma | Homo sapiens | CVCL_DP52 |
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
| Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | HNRNPA2B1 is a reader of the N(6)-methyladenosine mark in primary-miRNAs and promotes DROSHA processing to precursor-miRNAs. HNRNPA2B1 downregulated hsa-miR-29a-3p, miR-29b-3p, and miR-222 and upregulated miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced breast cancer cellMCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance. | |||
| Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
| Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
| Target Regulation | Down regulation | |||
| Responsed Drug | Tamoxifen | Approved | ||
| Pathway Response | TGF-beta signaling pathway | hsa04350 | ||
| Cell Process | Endocrine-resistance | |||
| In-vitro Model | MCF7/LCC9 | Invasive breast carcinoma | Homo sapiens | CVCL_DP52 |
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
Acute respiratory distress syndrome [ICD-11: CB00]
| In total 1 item(s) under this disease | ||||
| Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
| Response Summary | The knockout of methyltransferase 3 (N6-adenosine-methyltransferase complex catalytic subunit) removed the m6A modification of hsa-miR-29a-3p and reduced miR-29a-3p expression. These findings suggest that miR-29a-3p is a potential target that can be manipulated for ALI/ARDS. | |||
| Responsed Disease | Acute respiratory distress syndrome [ICD-11: CB00] | |||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| In-vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 |
| In-vivo Model | All the mice were randomly divided into three groups: the normal saline group (NS), the lipopolysaccharide + negative control group (LPS + NC), and the LPS + miR-29a-3p agomir group (LPS + Agomir). | |||
Fulvestrant
[Approved]
| In total 1 item(s) under this drug | ||||
| Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
| Response Summary | HNRNPA2B1 is a reader of the N(6)-methyladenosine mark in primary-miRNAs and promotes DROSHA processing to precursor-miRNAs. HNRNPA2B1 downregulated hsa-miR-29a-3p, miR-29b-3p, and miR-222 and upregulated miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced breast cancer cellMCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance. | |||
| Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
| Target Regulation | Down regulation | |||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
| Pathway Response | TGF-beta signaling pathway | hsa04350 | ||
| Cell Process | Endocrine-resistance | |||
| In-vitro Model | MCF7/LCC9 | Invasive breast carcinoma | Homo sapiens | CVCL_DP52 |
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
Tamoxifen
[Approved]
| In total 1 item(s) under this drug | ||||
| Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
| Response Summary | HNRNPA2B1 is a reader of the N(6)-methyladenosine mark in primary-miRNAs and promotes DROSHA processing to precursor-miRNAs. HNRNPA2B1 downregulated hsa-miR-29a-3p, miR-29b-3p, and miR-222 and upregulated miR-1266-5p, miR-1268a, miR-671-3p. Transient overexpression of HNRNPA2/B1 reduced breast cancer cellMCF-7 sensitivity to 4-hydroxytamoxifen and fulvestrant, suggesting a role for HNRNPA2/B1 in endocrine-resistance. | |||
| Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
| Target Regulation | Down regulation | |||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
| Pathway Response | TGF-beta signaling pathway | hsa04350 | ||
| Cell Process | Endocrine-resistance | |||
| In-vitro Model | MCF7/LCC9 | Invasive breast carcinoma | Homo sapiens | CVCL_DP52 |
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Regulator
Non-coding RNA
m6A Regulator: Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
| In total 4 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT05129 | ||
| Epigenetic Regulator | Prostate cancer associated transcript 6 (PCAT6) | |
| Regulated Target | Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) | |
| Crosstalk relationship | ncRNA → m6A | |
| Disease | Breast cancer | |
| Drug | Fulvestrant | |
| Crosstalk ID: M6ACROT05136 | ||
| Epigenetic Regulator | Prostate cancer associated transcript 6 (PCAT6) | |
| Regulated Target | Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) | |
| Crosstalk relationship | ncRNA → m6A | |
| Disease | Liver cancer | |
| Drug | Sorafenib | |
| Crosstalk ID: M6ACROT05383 | ||
| Epigenetic Regulator | hsa-miR-29a-3p | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Breast cancer | |
| Drug | Tamoxifen | |
| Crosstalk ID: M6ACROT05389 | ||
| Epigenetic Regulator | hsa-miR-29a-3p | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Breast cancer | |
| Drug | Fulvestrant | |
m6A Regulator: Methyltransferase-like 3 (METTL3)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT05580 | ||
| Epigenetic Regulator | hsa-miR-29a-3p | |
| Regulated Target | Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Acute respiratory distress syndrome | |
References